how many americans are on semaglutide About half of approve of using weight-loss drugs to treat obesity, AP-NORC poll finds Older Americans quitting weight-loss drugs

Plays a role in the immune system by detecting antigens and triggering immune responses against invaders

Implications for Metabolic Research Retatrutide represents a next-generation approach in peptide-based metabolic research, expanding beyond dual agonists to include triple hormonal targeting

People commonly experience some or all of the following side effects after stopping GLP-1 medications, says Goddard: Increased hunger (often noticeably stronger) Food noise, often described as the persistent mental chatter about eating and cravings Weight regain, which research shows can begin within weeks Changes in blood sugar control, particularly for people with type 2 diabetes Loss of some cardiometabolic benefits gained during treatment Improvement in GLP-1-related side effects such as nausea, constipation and bloating Not everyone experiences every one of these changes, and their severity varies widely

The normality and homogeneity of the results were tested using the KolmogorovSmirnov test and chi-squared test, respectively